PDF(Pubmed)
Abstract：
Checkpoint kinase 2 (CHEK2) plays a crucial role in responding to DNA damage and is linked to diverse cancer types. However, its significance in the prediction of prognosis and impacts on the immune status of clear cell renal cell carcinoma (ccRCC) remains unclear. This study aimed to identify the role of CHEK2 in prognosis and immune microenvironment of ccRCC. We analyzed transcriptome and clinicopathological data from the cancer genome atlas (TCGA) database and conducted functional enrichment analysis to explore molecular mechanisms. The relationship between CHEK2 and immune infiltration was evaluated, and drug sensitivity analysis was performed using the CellMiner database. The results showed that CHEK2 was an independent predictor of ccRCC prognosis and was closely associated with immune-related processes. Additionally, high expression of CHEK2 was linked to resistance to certain targeted drugs. These findings suggest that CHEK2 could serve as a biomarker for ccRCC, providing insights into tumor immune microenvironment alterations and immunotherapeutic response. Further investigation is needed to fully understand the potential of CHEK2 as a prognostic predictor and therapeutic target for ccRCC.
摘要：
检查点激酶2（CHEK2）在响应DNA损伤中起着至关重要的作用，并且与多种癌症类型有关。然而,其在肾透明细胞癌（ccRCC）预后预测和免疫状态影响中的意义尚不清楚。本研究旨在探讨CHEK2在ccRCC预后和免疫微环境中的作用。我们分析了癌症基因组图谱（TCGA）数据库中的转录组和临床病理数据，并进行了功能富集分析以探索分子机制。评价CHEK2与免疫浸润的关系，使用CellMiner数据库进行药物敏感性分析.结果显示CHEK2是ccRCC预后的独立预测因子,且与免疫相关过程密切相关。此外,CHEK2的高表达与某些靶向药物的耐药性有关。这些发现表明CHEK2可以作为ccRCC的生物标志物，提供对肿瘤免疫微环境改变和免疫治疗反应的见解。需要进一步的研究来充分了解CHEK2作为ccRCC预后预测因子和治疗靶点的潜力。
